Rhesus Monkey Rhadinovirus Uses Eph Family Receptors for Entry into B Cells and Endothelial Cells but Not Fibroblasts by Hahn, Alexander Steven & Desrosiers, Ronald C.
 
Rhesus Monkey Rhadinovirus Uses Eph Family Receptors for Entry
into B Cells and Endothelial Cells but Not Fibroblasts
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Hahn, Alexander S., and Ronald C. Desrosiers. 2013. Rhesus
monkey rhadinovirus uses Eph family receptors for entry into B
cells and endothelial cells but not fibroblasts. PLoS Pathogens
9(5): e1003360.
Published Version doi:10.1371/journal.ppat.1003360
Accessed February 19, 2015 12:07:37 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11177916
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAARhesus Monkey Rhadinovirus Uses Eph Family Receptors
for Entry into B Cells and Endothelial Cells but Not
Fibroblasts
Alexander S. Hahn, Ronald C. Desrosiers*
New England Primate Research Center, Harvard Medical School, Southborough, Massachusetts, United States of America
Abstract
Cellular Ephrin receptor tyrosine kinases (Ephrin receptors, Ephs) were found to interact efficiently with the gH/gL
glycoprotein complex of the rhesus monkey rhadinovirus (RRV). Since EphA2 was recently identified as a receptor for the
Kaposi’s sarcoma-associated herpesvirus (KSHV) (Hahn et al., Nature Medicine 2012), we analyzed RRV and KSHV in parallel
with respect to Eph-binding and Eph-dependent entry. Ten of the 14 Eph proteins, including both A- and B-type, interacted
with RRV gH/gL. Two RRV strains with markedly different gH/gL sequences exhibited similar but slightly different binding
patterns to Ephs. gH/gL of KSHV displayed high affinity towards EphA2 but substantially weaker binding to only a few other
Ephs of the A-type. Productive entry of RRV 26-95 into B cells and into endothelial cells was essentially completely
dependent upon Ephs since expression of a GFP reporter cassette from recombinant virus could be blocked to greater than
95% by soluble Eph decoys using these cells. In contrast, entry of RRV into fibroblasts and epithelial cells was independent
of Ephs by these same criteria. Even high concentrations and mixtures of soluble Eph decoys were not able to reduce by any
appreciable extent the number of fibroblasts and epithelial cells productively entered by RRV. Thus, RRV is similar to its close
relative KSHV in the use of Eph family receptors for productive entry into B cells and endothelial cells. However, RRV uses a
separate, distinct, Eph-independent pathway for productive entry into fibroblasts and epithelial cells. Whether KSHV also
uses an Eph-independent pathway in some circumstances or to some extent remains to be determined.
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Introduction
The gamma-2 herpesviruses, also called rhadinoviruses, are a
distinct subfamily of the lymphotropic herpesviruses. The rhesus
monkey rhadinovirus (RRV) is a natural infectious agent found at
high frequency in both captive and feral populations of rhesus
monkeys (Macaca mulatta) [1]. RRV is a rhesus monkey homolog of
the human Kaposi’s sarcoma-associated herpesvirus (KSHV,
human herpesvirus 8, HHV-8). RRV and KSHV share a nearly
identical genome organization, high gene-for-gene sequence
similarity, and an identical array of captured host genes [2,3].
Unlike KSHV, RRV can be grown lytically and to high titer on
monolayer cells, principally early passage primary rhesus fibro-
blasts. Both RRV and KSHV establish persistent infection of B cells
in vivo[4,5]andof established B cell lines[6,7].The B cell appearsto
be the principal site of persistenceof both RRVand KSHV in vivoin
their natural hosts [4,5,8]. RRV has been associated with B cell
malignancies similar to those caused by KSHV [9–11]. While
RRV-positive retroperitoneal fibromatosis has been observed in
animalsinoculatedwith RRVstrain17577[10],notightassociation
of RRV with solid tumors has been reported.
Cellular integrins, either alpha3beta1 [12] or alphaVbeta3 [13],
have been reported to serve as receptors for mediating entry of
KSHV into target cells. The KSHV interaction with integrins is
mediated by glycoprotein B and it is not known whether other
viral glycoproteins may participate in the integrin-mediated entry
process. Interestingly, neither the RGD-sequence in gB nor
binding of gB to integrin alpha3beta1 or alphaVbeta3 is conserved
between KSHV and RRV [13]. DC-SIGN has also been reported
to function as a receptor for KSHV on activated B cells [14].
However, interaction of DC-SIGN with a specific viral glycopro-
tein has not been demonstrated and, as with HIV-1 [15], DC-
SIGN may be simply serving as an adhesion molecule on the
surface of the cells to bring virions into close proximity to the
entry-mediating receptors. In 2007, Kaleeba et al. reported that
the cysteine transporter xCT serves as a receptor for KSHV
glycoprotein-mediated membrane fusion [16]. While function of
xCT in KSHV glycoprotein-mediated fusion has been demon-
strated, additional details on whether xCT is a ‘classical’ receptor
that directly binds to a KSHV glycoprotein or rather a critical host
factor for the fusion process are so far not available. Another
report by Veettil et al. claims that xCT interacts with integrins in a
time-dependent manner upon KSHV infection and affects viral
gene expression rather than fusion and entry [17]. xCT, like other
members of the SLC7 amino acid transporter family, dimerizes
with a heavy chain 4F2hc/CD98 [18]. These dimers of CD98
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16with a light chain from the SLC7 family form the 4F2 antigen [19]
which is also known as fusion regulatory protein 1 (FRP-1) [20]
and appears to be involved in a multitude of different membrane
fusion processes [20–22]. This supports a role for xCT in fusion,
but perhaps not as a classical receptor whose engagement triggers
the viral fusion protein. More recently, Hahn et al. reported that
an Ephrin receptor tyrosine kinase, EphA2, serves as a cellular
entry receptor for KSHV [23]. EphA2 binds with high avidity to
the gH/gL glycoprotein complex of KSHV and several different
approaches of interfering with this receptor interaction inhibited
entry of KSHV into a variety of different target cells.
Here, we describe the conserved use of Ephrin receptor tyrosine
kinases (Ephs) for entry of the related rhadinovirus RRV into
specific target cells; entry of RRV into B cells and endothelial cells
could be blocked by more than 95% with soluble Eph decoys. By
the same means, cell-cell transmission of KSHV into a B cell line
could be abrogated. These results provide support for the
conserved use of Eph by both KSHV and RRV for entry into B
cells and endothelial cells. However, our results indicate that RRV
can also utilize a separate, distinct entry pathway that is
independent of Ephs for productive entry into fibroblasts and
epithelial cells. This Eph-independent pathway is apparently not
available to any appreciable extent to RRV in B cells and
endothelial cells.
Results
Identification of Ephs as interaction partners for RRV gH/
gL complexes
To identify cellular proteins that associate with the extracellular
domain of gH/gL complexes of RRV in an unbiased way, we
performed large-scale, two-step immunoprecipitation. RRV 26-95
and RRV 17577 have highly divergent gH and gL sequences [24];
therefore, gH and gL from both isolates were included. After a first
pulldown of proteins from cell lysates from 293T cells with gH-Fc/
gL complexes from RRV 26-95, RRV 17577 or KSHV
immobilized on Streptactin, the complexes were specifically eluted
with desthiobiotin. Subsequently, the protein complexes were re-
precipitated from the eluate with Protein A to eliminate
background and then subjected to gel electrophoresis and staining
with colloidal coomassie. Examples of the stained gels are shown in
Fig. 1A. Co-precipitating proteins were excised from the gel and
identified by tryptic digest, LC-MS and peptide sequencing.
KSHV gH-Fc/gL was included in our experiments as a reference
(Fig. 1A rightmost three lanes), with a mixed dimer between
KSHV gH-Fc and RRV 26-95 gL as an additional control.
Proteins of an apparent molecular weight of approximately
110 kDa were found to precipitate with gH/gL complexes of
both RRV strains and were identified as a mixture of Ephs
(Fig. 1B). As previously reported [23], KSHV gH/gL precipitated
predominantly with EphA2 (Fig. 1B).
Specificity of RRV and KSHV gH/gL complexes for Ephs
As a first approach of verifying the above results, we performed
pairwise co-immunoprecipitations with each of the three gH/gL
complexes and each of the 14 Ephs expressed as full length
proteins with a C-terminal myc epitope tag (Fig. 1C). We found
both RRV gH/gL complexes to interact prominently with EphB3
and KSHV gH/gL to interact with EphA2 under the conditions
used in these immunoprecipitation experiments. These conditions
appeared to eliminate some interactions with Ephs other than
EphB3 that were detected with the gH/gL complexes of both
RRV strains in the initial mass spectrometry experiments. To
achieve a wider dynamic range and to better compare binding of
the rhadinoviral gH/gL complexes to different Ephs, 293T cells
were transfected with expression plasmids for the 14 known
human Ephs and binding of the individual gH/gL complexes to
the transfected cells was assayed by flow cytometry (Fig. 2A). The
cells were stained for both the Eph constructs via their C-terminal
myc tag and the gH-Fc/gL complexes via the Fc portion. The
ratio of the geometric mean of the fluorescence of the bound gH-
Fc/gL complex (Alexa488 via secondary antibody to Fc-portion)
divided by the geometric mean of the fluorescence of the detected
Ephs (Cy5 via myc-tag) was calculated as a semi-quantitative
gauge for binding (Fig. 2B, Suppl. Fig. S1). The uniformly low and
practically identical ratios for binding of the Fc control protein
(Fig. 2B, left) for each Eph protein validated this approach. The
RRV gH/gL complexes of both RRVs were able to bind to both
A and B type Ephs, slightly favoring the B-type EphB3. KSHV on
the other hand bound EphA2 most efficiently of all gH/gL-Eph
pairs and was found to interact with other A-type Ephs only
weakly, and not with B-type Ephs. Interestingly, all the gH/gL
complexes shunned EphB4 completely, with no detectable binding
in both assays.
Relevance of Eph-driven entry for RRV infection of
primary cells and cell lines of different lineages
To examine the actual usage of Ephs as receptors for RRV
entry, blocking experiments were performed. Cell lines and
primary cells derived from B cells, endothelial cells, fibroblasts
and epithelial cells were infected with RRV-GFP 26-95 which was
pre-incubated with soluble Eph-Fc fusion proteins to compete with
the cellular Ephs for binding to the viral gH/gL complex. Eph-Fc
fusion proteins (R&D Systems) were used as decoy receptors, all
but EphA2-Fc of human origin. Murine EphA2-Fc was used in
order to utilize identically prepared proteins from the same
supplier since human EphA2-Fc was not available. Murine and
human EphA2 are highly homologous (92% amino acid identity,
Suppl. Table S1, both function as KSHV receptor [23], and
soluble forms of both molecules block KSHV entry, see below). As
RRV efficiently enters cells of both human and rhesus origin, we
chose a selection of cells available to us from both species and
infected those cells with RRV-GFP 26-95 reporter virus after pre-
incubation of the virus with the soluble Ephs as decoys. We found
Author Summary
Here we show that the gH/gL glycoprotein complex of
rhesus monkey rhadinovirus binds to and mediates entry
of virus into target cells via cellular Ephrin receptor
tyrosine kinase proteins. Rhesus monkey rhadinovirus is a
gamma-2 herpesvirus that is a close homolog of the
human Kaposi’s sarcoma-associated herpesvirus (KSHV;
HHV-8). While KSHV uses EphA2 principally or exclusively
for entry, RRV is able to use a broader range of both A-type
and B-type Eph receptors. The use of Eph proteins as
receptors is conserved despite substantial sequence
variation in gH/gL between two RRV strain types and
between RRV and KSHV. Importantly, while entry of RRV
into B cells and endothelial cells was completely depen-
dent on the Eph receptors by a variety of criteria, entry of
RRV into fibroblasts and epithelial cells was essentially
independent of Eph receptors by these same criteria. Thus,
RRV uses a separate, distinct, Eph-independent pathway
for productive entry into fibroblasts and epithelial cells.
Whether KSHV also uses an Eph-independent pathway in
some circumstances or to some extent remains to be
determined.
Ephs Are Entry Receptors for RRV and KSHV
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infection of primary rhesus fibroblasts was at most marginally
affected by block with soluble Ephs (inhibition ,50% vs EGFR-Fc
control, Fig. 3A, lower panel). In stark contrast, entry of RRV 26-
95 into both B cells and endothelial cells was heavily impaired or
even abolished by soluble Ephs at 1 mg/ml (Fig. 3A, upper and
mid panels). In dose-inhibition curves (Fig. 3B), it became evident
that soluble Ephs abolish RRV 26-95 entry into BJAB B cells
already at low concentrations, whereas entry into 293T and rhesus
fibroblasts was affected only marginally and inhibition did not
increase with increasing concentrations of the soluble Ephs.
A similar picture was obtained by blocking entry of RRV 26-95
into several cell lines by pre-incubation of the cells with soluble
Ephrin-Fc proteins (Fig. 4). Ephrins are the natural ligands of the
Eph receptors. The name ‘Ephrin’ is itself an abbreviation derived
from ‘Eph family receptor interacting protein’ [25]. Soluble
Ephrin-Fc ligands may block access to the Ephs by both interfering
with binding and perhaps also by triggering endocytosis, thus
removing the Ephs from the cell surface. There are eight Ephrins,
classified into A- and B-type. A-type Ephrins are anchored in the
plasma membrane through a GPI-anchor, the B-type Ephrins are
classical type I transmembrane proteins [25,26]. This classification
also corresponds to the ligand specificities, with A-type Ephrins
binding preferentially A-type Ephs and B-type Ephrins binding B-
type Ephs [27], although some cross-binding has been reported
[28]. The actual numbers of the Ephs and Ephrins are not
indicative of their specificities (Suppl. Fig. S2). A commercially
available panel of soluble human and murine Ephrin-Fc fusion
proteins (fused to human IgG1 Fc) covering all Ephs with their
specificities was used; murine Ephrins bind human receptors and
vice versa and the specificities of single Ephrins usually overlap
several receptors with different affinities (according to manufac-
turer, Suppl. Fig. S2). Entry of RRV 26-95 into the two B cell lines
(Fig. 4, BJAB and 309-98, leftmost panels) was strongly inhibited
by Ephrin ligands. Entry into rhesus microvascular endothelial
cells (rhMVEC, Fig. 4 top, 3
rd panel) was also inhibited but to a
Figure 1. Identification of cellular interaction partners of RRV gH/gL. (A) Purification of proteins interacting with the ectodomains of RRV 26-
95, RRV 17577 and KSHV. Lysates of 293T cells were incubated with gH-Fc/gL (Strep epitope-tagged) complexes from RRV 26-95 or 17577 pre-
coupled to Streptactin beads. After elution with desthiobiotin, the eluate was re-precipitated with Protein A sepharose, washed, and subjected to gel
electrophoresis followed by colloidal coomassie staining. Arrows indicate Eph-containing bands. (B) Summary of proteins identified in the indicated
band with the respective gH/gL complexes. The numbers of peptides identified for each protein in one sample are given in brackets. Where more
than one number is given, several samples were analyzed and the first number is from the first sample, the second from the second sample. (C)
Pairwise immunoprecipitation of individual Eph proteins with gH/gL of KSHV, RRV 26-95 and RRV 17577. Full length Eph proteins (myc epitope-
tagged) were recombinantly expressed in 293T cells. The lysates were normalized for equal expression with the lysate of non-transfected 293T cells.
The recombinant Eph proteins were immobilized with myc antibody on Protein G beads in a first round of immunoprecipitation. The immobilized
proteins were then incubated with equal amounts of lysates from 293T cells transfected with expression constructs for the respective gH (V5 epitope-
tagged)/gL complexes, followed by washing and Western Blot analysis.
doi:10.1371/journal.ppat.1003360.g001
Ephs Are Entry Receptors for RRV and KSHV
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single Ephrin, but to a noticeable extent by several different
Ephrins indicating involvement of both A- and B-type Ephs. These
findings mirror the broad specificity for Eph-binding of RRV gH/
gL described above (Figs. 1 and 2). The profile of effective Ephrins
clearly varied from one cell to another, likely reflecting usage of
different Ephs on different cells. For example, entry of RRV 26-95
into BJAB (B cell derived) was blocked most effectively by A-type
Ephrins, which indicates A-type receptor usage. On the other
hand, entry into 309-98 (B cell derived) cells and R8 (endothelial)
was blocked most effectively by B-type Ephrins, which indicates B-
type receptor usage.
Relevance of Eph engagement for KSHV entry into
adherent cells and a B cell line
Completely analogous to our experiments with RRV 26-95,
KSHV was pre-incubated with soluble Ephs before infection of
293T cells, rhesus fibroblasts, human umbilical vein endothelial
cells (HUVEC), and R8 rhesus endothelial cells. Only soluble
mEphA2-Fc but not EphA1-Fc, EphA7-Fc, EphB2-Fc or EphB3-
Fc was able to block entry of KSHV into those cells at 1 mg/ml
(Fig. 5A). Recombinant human EphA2 (without Fc part)
performed comparably to recombinant murine EphA2-Fc protein
(Fig. 5A rightmost panel). Blocking with soluble Ephrins at 5 mg/
ml affected KSHV infection only when the cells were incubated
with A-type Ephrins, and with EphrinA4-Fc having the greatest
effect (Fig. 5B). This fits with EphA2 as the principal receptor
when compared to the binding properties of the individual Ephrin-
Fc constructs used (Suppl. Fig. S2). EphA2 binds efficiently to the
Ephrin A1, A3 and A4 Fc-fusion proteins that were effective in our
blocking assays. While EphA2 and EphA4 both strongly bind to
EphrinA4-Fc, EphA4 also avidly binds to EphrinA5-Fc, which was
without a pronounced effect in our blocking assays and is bound
very weakly by EphA2. Moreover, EphrinA1-Fc and EphrinA3-Fc
were also active in our KSHV blocking assay but do not interact as
avidly with EphA4 as does the inactive EphrinA5-Fc. Thus,
EphA2 binds with high avidity to all Ephrins that were active in
our blocking assay, but only weaker to those that were inactive,
while the ligand preferences of EphA1, EphA4, EphA5 and
Figure 2. Interaction of rhadinoviral gH/gL complexes with Eph family receptors. (A) Binding of soluble gH-Fc/gL complexes to Eph family
proteins. 293T cells were transfected with the indicated myc epitope-tagged Eph constructs. The cells were fixed and permeabilized, and both Eph
expression and binding of soluble gH-Fc/gL complexes from RRV 26-95, RRV 17577 or KSHV at 10 nM was assayed by flow cytometry. Fc was used as
a control. (B) As a semi-quantitative gauge of binding, the ratio of the geometric mean fluorescence intensities for Eph-expression and gH-Fc/gL
binding was calculated. The whole area of the dot blot containing cells positive for Cy5 and/or Alexa488 except for the box gate containing negative
cells in the lower left corner was analyzed, and the ratio of the geometric mean of the fluorescence intensity (MFI) for bound gH-Fc/gL (Alexa488)
over the MFI for Eph expression (Cy5) was calculated. Values for the Fc control protein are shown to the left and represent the assay background.
doi:10.1371/journal.ppat.1003360.g002
Ephs Are Entry Receptors for RRV and KSHV
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KSHV.
Infection of B cells with KSHV proved to be technically more
difficult than infection with RRV 26-95, but was achieved by co-
culturing BJAB B cells with lytically induced iSLK.219, as recently
described by Myoung et al. [7]. Co-culture was performed in the
presence of soluble Ephs, Ephrins or a control protein. The CD20-
positive population representing the B cells was analyzed for GFP
expression. Entry into BJAB was again inhibited by soluble
EphA2-Fc (Fig. 6A) and A-type Ephrins (Fig. 6B). Surprisingly, in
this setting all A-type Ephrins blocked entry to background levels.
Blockage by both EphA2 decoy receptor and Ephrin ligands at
5 mg/ml resulted in virtually complete inhibition of entry as
opposed to the results with adherent cells, where always a certain
residual level of entry was observed.
Cell specific use of Ephs by RRV
When directly compared, a striking difference between endo-
thelial cells and fibroblasts with regard to infection with RRV 26-
95 became obvious (Figs. 3 and 4). There was no or only very little
effect of Eph blocking agents on RRV 26-95 entry into fibroblasts,
with minor variations between no or little effect between
experiments. It could be argued that the high functional MOI
close to 1 achieved on early passage fibroblasts (Fig. 3B) might
mask inhibition because the assay has already reached its upper
saturation limit. We thus used a higher passage, less permissive
batch of fibroblasts (lower functional MOI with same virus) for
another experiment, and compared highly permissive HUVEC
cells head-to-head. HUVEC were chosen because of all endothe-
lial cells tested, HUVEC were the ones with the apparently
smallest effect of Eph decoy receptor blocking (Fig. 3A). Again,
RRV 26-95 entered rhesus fibroblasts apparently unaffected by
block with soluble Ephs or combinations of soluble Ephs even at
20 mg/ml (Fig. 7A and 7C, left). We do not know the significance
of the slight increase in entry into fibroblasts with two of the Eph-
Fc proteins at high concentrations in Fig. 7A. In stark contrast to
the result with fibroblasts, when the same Eph-pre-incubated RRV
inoculum was used on HUVEC in parallel, RRV infection was
greatly diminished (Fig. 7A, right). Block with the RRV interacting
Ephs (EphA7, EphB2, EphB3) as soluble decoys inhibited entry of
RRV into HUVEC almost completely (Fig. 7A and 7C, right). In
contrast to RRV, KSHV entry into both fibroblasts and HUVEC
Figure 3. Inhibition of RRV entry by soluble Eph proteins. (A) Inhibition of RRV entry into cells of different lineages through block with soluble
Eph proteins. RRV-GFP 26-95 was pre-incubated with EphA1-Fc, mEphA2-Fc, EphB2-Fc, EphB3-Fc or EGFR-Fc as a control prior to infection. All
proteins were used at 1 mg/ml. (n=4 for rhMVEC, R8 and HUVEC, else n=3; error bars indicate sd) (B) Dose dependent inhibition of RRV entry by
soluble Eph proteins. BJAB, rhesus fibroblasts and 293T cells were infected with RRV-GFP 26-95 that was pre-incubated at the indicated
concentrations prior to infection with either murine EphA2-Fc (black boxes), EphB3-Fc (black triangles) or EGFR-Fc (open circles) as control. Viral entry
as indicated by GFP expression was quantified by flow cytometry. (n=3 per data point for 293T and BJAB, n=2 for rhesus fibroblasts; error bars
indicate sd for n=3 or range for n=2).
doi:10.1371/journal.ppat.1003360.g003
Ephs Are Entry Receptors for RRV and KSHV
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twenty times the concentration of soluble decoy receptor as
compared to Fig. 5, marginal inhibition of KSHV entry was also
observed with EphA1-Fc (222%) and with EphA7-Fc (235%) on
rhesus fibroblasts; this could reflect weak interaction of those two
Ephs with KSHV gH/gL. Obviously, KSHV and RRV differ with
respect to entry into fibroblasts, but not into endothelial cells. The
extreme discrepancy between RRV entry into rhesus fibroblasts
and into HUVEC was clearly visible from day one through three
post infection, not only with the low-permissive fibroblasts used in
Fig. 7A but also with primary fibroblast that exhibit a functional
MOI comparable to HUVEC (Fig. 7C).
We next investigated the influence of MOI on degree of
inhibition using a high-titered RRV-YFP 26-95. A 1:20 dilution of
this stock infected 95% of HUVEC cells, indicating an MOI
substantially greater than 1 at this dilution on those cells (Suppl.
Fig. S3A). We used both numbers of YFP-positive cells (Suppl. Fig.
S3A) and mean fluorescence intensity (Suppl. Fig. S3B) as the
readouts and we used 10 mg/ml of EphB3-Fc for blocking (Suppl.
Figs. S3A and S3B). At the highest levels of input virus, inhibition
based on total number of YFP-positive HUVEC dropped from
over 90% to as low as 65% (Fig. S3C). However, based on mean
YFP fluorescence intensity, which is not saturated at high MOI,
the degree of inhibition was over 95% even at the highest MOI on
HUVEC cells (Suppl. Figs. S3B and S3D). Although some
inhibition of entry into fibroblasts by EphB3-Fc was observed in
this experiment, the extent of inhibition was much less than with
HUVEC. In a total of four experiments with high concentrations
of soluble Eph decoy receptors so far, we have seen low levels of
inhibition in fibroblasts in two of them (Fig. 3A and Suppl. Fig.
S3A) and no inhibition in two others (Fig. 3B and Fig. 7A), likely
reflecting variation in batch and passage history of these primary
cells. Nonetheless, even when measuring at earlier timepoints
which is slightly more sensitive towards detecting inhibition,
reduction of entry as determined by the number of positive cells is
limited to 50% maximum in fibroblasts as compared to 99% in
HUVEC and does not respond to increasing concentrations of the
blocking agent (Suppl. Fig. S3E).
We next asked whether the dependence on Ephs for productive
entry of RRV into HUVEC cells as measured by reporter gene
expression is reflected by levels of incoming virion DNA reaching
the nucleus. Nuclei were prepared from infected cells at four
hours post infection in a confluent monolayer six well plate under
conditions that yield 70–95% (MOI.1) infected cells. The
quality of the separation protocol was controlled by Western Blot
analysis on the nuclear marker lamin B and the cytoplasmic/
cytoskeletal marker tubulin (Fig. 8A). Measurement of the
number of RRV genomes in the nuclear fraction of fibroblasts
and HUVEC by quantitative realtime PCR confirmed our
previous results in that EphB3-Fc soluble decoy receptor indeed
inhibited the accumulation of virion DNA in the nucleus. Nuclear
accumulation of the viral genome in HUVEC four hours post
infection was significantly reduced by 74% in the presence of
5 mg/ml EphB3-Fc (Fig. 8B), whereas nuclear delivery to
Figure 4. Block of RRV entry by soluble Ephrins. Primary cells and cell lines were incubated with the soluble Ephrin-Fc fusion proteins at 5 mg/
ml for 30 minutes prior to infection with GFP encoding RRV 26-95. Entry was quantified by flow cytometry. EGFR-Fc or mEphA2-Fc were used as
controls in addition to PBS. (n=4 for rhMVEC , LEC, and R8, else n=3; error bars indicate sd).
doi:10.1371/journal.ppat.1003360.g004
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PLOS Pathogens | www.plospathogens.org 6 May 2013 | Volume 9 | Issue 5 | e1003360Figure 5. Inhibition of KSHV entry by soluble Eph proteins and soluble Ephrins. (A) rKSHV.219 was pre-incubated with the indicated
soluble Eph-Fc fusion proteins at 1 mg/ml for 45 min. Entry was quantified by flow cytometry. (n=3; error bars indicate sd) (B) Inhibition of KSHV
entry by soluble Ephrins. Target cells were pre-incubated with the indicated Ephrin-Fc fusion proteins at 5 mg/ml for 30 min followed by infection
with rKSHV.219. Entry was quantified as in (A). PBS and EGFR-Fc serve as controls. (n=4 for HUVEC and R8, else n=3; error bars indicate sd).
doi:10.1371/journal.ppat.1003360.g005
Figure 6. Inhibition of KSHV cell-cell transmission into a B cell line by soluble Eph proteins and soluble Ephrins. BJAB B cells were co-
cultured for 10 days (A) or 4 days (B) with lytically induced iSLK.219 cells in the presence of the indicated proteins at 5 mg/ml. The cells were then
harvested and analyzed for expression of the GFP reporter gene by flow cytometry. BJAB cells were distinguished from iSLK.219 cells by a two-step
gating strategy, first selecting by FSC/SSC for the B cell population and then by gating for CD20 expression. The percentage of green CD20-positive
cells from co-culture with non-induced iSLK cells represents the assay background. PBS and EGFR-Fc serve as controls. (n=3; error bars indicate sd).
doi:10.1371/journal.ppat.1003360.g006
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PLOS Pathogens | www.plospathogens.org 7 May 2013 | Volume 9 | Issue 5 | e1003360Figure 7. Differential entry of KSHV and RRV into fibroblasts and endothelial cells. (A) RRV-GFP 26-95 was pre-incubated with the
indicated Eph-Fc fusion proteins at 20 mg/ml or a mix of three at 6.66 mg/ml. The virus was then divided and inoculated onto primary rhesus
fibroblasts or HUVEC cells. Entry was quantified by flow cytometry. (n=3; error bars indicate sd) (B) KSHV was pre-incubated with the indicated
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not significant.
Importance of vesicle acidification for Eph-mediated
entry
A number of reports implicate endocytosis followed by vesicle
acidification as the main mechanism of entry for KSHV [29–31]
and RRV [32]. Likewise, lipid rafts were reported to play a major
role in KSHV entry [33]. We thus examined the Eph-dependent
entry pathway of RRV 26-95 into R8 endothelial cells and the
largely Eph-independent entry pathway into rhesus fibroblasts
with respect to sensitivity towards inhibition of vesicle acidifica-
tion and lipid raft formation. KSHV, which enters both cell types
principally in an Eph-dependent fashion, was analyzed in
parallel. Bafilomycin A, a highly specific inhibitor of the vacuolar
ATPase, or methylbetacyclodextrin, a cholesterol depleting agent
that destroys lipid rich microdomains [34], were chosen for
inhibition of vesicle acidification and lipid raft formation,
respectively. In addition, VSV-G and A-MLV pseudotyped
lentiviruses encoding GFP were included as controls for the
specificity of bafilomycin A on vesicle acidification and cell
viability. VSV-G mediated fusion is pH dependent whereas A-
MLV mediated fusion is not [35]. We found that inhibition of
vesicle acidification strongly interfered with entry of RRV and
KSHV into both R8 endothelial cells and rhesus fibroblasts
(Fig. 9A, right panels) and also with entry of free RRV 26-95 into
a B cell line (Fig. 9B, right panel). The dose-response inhibition
curves obtained for RRV and KSHV in the presence of
bafilomycin A were virtually indistinguishable from curves
obtained with a VSV-G pseudotyped lentivirus, while a A-
MLV pseudotyped lentivirus was unaffected (Fig. 9A, right
panels). Cholesterol depletion by MBCD yielded a slightly more
nuanced picture. We found cholesterol depletion by MBCD to
effectively inhibit entry of RRV 26-95 into all cells tested (Fig. 9A
and 9B, left panels). KSHV on the other hand was only
moderately affected by MBCD on R8 endothelial cells, and not at
all on rhesus fibroblasts.
Discussion
There are common features and there are also differences when
comparing KSHV and RRV for productive entry into target cells.
The principal common feature is the recognition and use of Eph
receptors by viral gH/gL in the entry process. Productive entry
could be blocked by soluble forms of specific Ephs when used as
blocking agents (Figs. 3 and 5A), and soluble forms of specific
Ephrins (Figs. 4 and 5B), i.e. the ligands for the Eph receptors,
were also able to specifically inhibit productive viral entry. Both
KSHV and RRV appear to use receptor-mediated endocytosis for
the productive entry process (Figs. 9A and 9B). Interestingly, entry
of RRV and KSHV was always sensitive to inhibition of vesicle
acidification. In contrast, only entry of RRV was generally
sensitive to cholesterol depletion. Entry of KSHV into R8
endothelial cells was only marginally affected and entry into
rhesus fibroblasts was not sensitive to cholesterol depletion (Fig. 9A,
left panels). This implicates low pH as a common feature in entry,
but not the use of lipid rafts, at least not on all cell types. An
interesting question here would be whether cell-specific localiza-
Eph-Fc fusion proteins at 20 mg/ml prior to infection of rhesus fibroblasts or HUVEC and entry was quantified as above. (n=3; error bars indicate sd)
(C) HUVEC and rhesus fibroblasts were infected with RRV-GFP 26-95 in the presence of either EphB3-Fc or EGFR-Fc (control) at 10 mg/ml. Pictures
were taken on day 1, 2 and 3 after infection (BF: brightfield, green: GFP).
doi:10.1371/journal.ppat.1003360.g007
Figure 8. Nuclear delivery of RRV into HUVEC is Eph-dependent. (A) Western Blot analysis of nuclear fractions (nuclei) and whole cellular
lysates (WCL) prepared from HUVEC and rhesus fibroblasts. Whole cellular lysate and nucleic fraction were probed for lamin B (nuclear marker) and
tubulin (cytoskeleton). (B) Quantification of RRV genomes in the nuclear fraction 4 h post infection. HUVEC or rhesus fibroblasts were infected with
RRV for 4 h. Virus was pre-incubated with EphB3-Fc or EGFR-Fc (control) for 45 minutes. The cells were washed, harvested by trypsinization, and
nuclei were prepared. Total DNA was extracted from the nuclei and copy number of the viral genome and the cellular GAPDH locus was quantified by
realtime PCR. The ratio of RRV/GAPDH copy number for the control infection (EGFR-Fc) in each cell type was set to 100%. The average of three
independent experiments is shown, error bars represent the standard deviation. The difference in HUVEC is significant (p=0.00003), the difference in
rhesus fibroblasts is not (p=0.125) (n=3, two sided student’s t-test with unequal variance).
doi:10.1371/journal.ppat.1003360.g008
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least for some cells, EphA2 was described to be lipid raft associated
[36].
RRV gH/gL appears to recognize a broader range of Eph
receptors than gH/gL of KSHV, and the highest affinity
‘preferred’ receptor differs between the two viruses: EphA2 for
KSHV and EphB3 for RRV. Inhibition by the soluble Eph
receptor decoys mirrors this preferred affinity; RRV was blocked
by soluble EphB3 but not EphA2 whereas KSHV was blocked by
soluble EphA2 but not EphB3. The ability of RRV strain 26-95
and RRV strain 17577 to target a similar spectrum of Ephs (Fig. 2)
is quite remarkable given the impressive divergence in sequences
in the external domain of gH and in gL [24]. The biggest
difference between the two seems to be that strain 17577 exhibits a
much higher affinity towards EphA2. It remains to be determined
whether the fact that EphB4 is not bound by all three viruses has
Figure 9. Rhadinovirus entry is dependent on vesicle acidification. (A) R8 endothelial cells or rhesus fibroblasts were pre-incubated for 1 h
with MBCD or bafilomycin A at the indicated concentrations. The cells were then inoculated with rKSHV.219 (black line, circles) or RRV-GFP 26-95
(black line, diamonds). SIVmac329deltanef-GFP pseudotyped with A-MLV (dashed line, open circles) or VSV-G (dashed line, open boxes) envelope
proteins was used in parallel as controls. Entry was assayed by GFP expression after 48 h. (B) The same assay as in (A) was performed with BJAB B cells
with RRV-GFP 26-95 (black diamonds). An exclusion dye based cell viability assay (dashed line, open boxes) was included to control for toxicity. (n=3;
error bars indicate sd).
doi:10.1371/journal.ppat.1003360.g009
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endothelium [37] and is downregulated through a phenotypic
switch from venous to arterial endothelium in KS [38].
The blocking experiments with different Ephrin ligands (Fig. 4)
clearly demonstrate that RRV is capable of not only binding but
also using both A- and B-type Ephs for entry. KSHV on the other
hand relies heavily on EphA2, and the spectrum of Ephrins with
blocking activity clearly implicates EphA2 (Fig. 5B), which also fits
the binding profile of KSHV gH/gL (Figs. 1 and 2) and previous
observations [23,36]. Only cell-cell transmission of KSHV into
BJAB was also sensitive to inhibition with a broader spectrum of
A-type Ephrins, but not B-type Ephrins (Fig. 6). The explanation
for this broader spectrum with cell-cell transmission of KSHV in
BJAB cells is not clear at the present time.
Our data argue strongly that Eph family receptors are serving as
classic receptors for receptor-mediated entry of RRV into target B
and endothelial cells, rather than some facilitating function such as
cellular activation. The efficiency with which productive entry and
delivery of the viral genome to the nucleus (Fig. 8B) could be
blocked by Eph-specific reagents and the specificity of the effects
are the strongest arguments to support this contention. Productive
entry could be routinely blocked to .90%, even by relatively low
concentrations of soluble EphB3 receptor (Fig. 3) and by soluble
forms of the natural ligands (Ephrins) (Fig. 4). The inability of
these same reagents (soluble EphB2 and EphB3 decoy receptors)
to appreciably impact productive entry of KSHV (only susceptible
to EphA2 decoy receptor) into the very same cells or of the same
RRV stock into fibroblasts and epithelial cells argues not only for
the specificity of the effect but also for the use of Ephs as receptors
for receptor-mediated entry into B and endothelial cells.
Our data show convincingly that RRV achieves productive
entry into fibroblasts and epithelial cells independent of Eph
receptor usage (Fig. 2B, Figs. 7A and 7C, Fig. 8B, Suppl. Fig. S3)
and, therefore, must be using different mediators for entry into
these cells. While Ephs are expressed on those cells, the Eph-
independent route of entry is predominant.
There is precedent in the herpesvirus family for different modes
of entry for the same virus into different types of cells. In the case
of EBV, different gH/gL complexes are used to infect lymphocytes
and epithelial cells. EBV gH/gL associates with gp42 for the
infection of B cells through type II HLA molecules [39]; for
epithelial cells, EBV gH/gL binds directly to integrins to trigger
fusion [40]. In the case of cytomegalovirus, a pentameric complex
of gH/gL/UL128/UL130/131 is used for the infection of
epithelial and endothelial cells [41], but the accessory glycopro-
teins UL128-131 are dispensable for infection of fibroblasts [42].
Based on the precedent of these other herpesviruses, it is logical
to speculate that gH/gL of RRV may similarly complex with
another envelope protein to mediate entry into fibroblasts and
epithelial cells. It is also possible that entry of RRV into fibroblasts
and epithelial cells may be independent of gH and/or gL. Along
these lines, MHV-68 deleted in the gL locus has been shown to be
replication competent [43]. The gamma-2 herpesviruses encode
fewer glycoproteins than other subfamilies of herpesviruses and
thus are convenient for the investigation of these alternate modes
for viral entry. Furthermore, the difference between RRV’s
dependence on Ephs for entry into B and endothelial cells and
its independence of Ephs for entry into fibroblasts and epithelial
cells is dramatic. Whatever receptor is being used by RRV for
entry into fibroblasts and epithelial cells, our results predict its
absence or lack of function in B cells and endothelial cells.
Does KSHV differ from RRV in terms of its ability to use an
Eph-independent route for entry? Certainly, productive entry of
KSHV into all of these same cell types is significantly blocked by
soluble EphA2 receptor decoys or soluble Ephrins, and sometimes
even abrogated (Figs. 5 and 6), [23]. However, there is a certain
residual low level of infection in many cell types that can’t be
readily blocked by interfering with Eph receptor function, also
noticed in a previous study [23]. More work will be needed with
KSHV to clarify this issue.
With regardtothevirus-associated malignancies,Ephsclearlyare
the relevant receptor family. Our data demonstrate that Ephs are
not only crucial for infection with free virus, but also for cell-cell
transmission of KSHV to a B cell line (Fig. 6). Entry of both RRV
and KSHV into endothelial cells and B cell lines was dramatically
inhibited by all ways of interfering with Eph receptor-engagement.
From a wider perspective, it is fascinating that both tumor viruses
use receptors whose expression or function is massively deregulated
in tumors [44]. It is tempting to speculate what additional roles Eph
receptors may play in rhadinovirus-associated tumorigenesis, also
with respect to the differences in the receptor specificities of KSHV
and RRV, and whether these differences contribute to the ability of
KSHV to cause Kaposi’s sarcoma.
Materials and Methods
Cell culture and transfections
293T cells (ATCC), Hela cells (ATCC) and primary rhesus
fibroblasts (NEPRC, Harvard Medical School) were cultured in
DMEM supplemented with 10% fetal bovine serum (FBS)
(Invitrogen), 25 mM HEPES (Invitrogen), 100 Units/ml Penicillin
(Invitrogen), 100 mg/ml Streptomycin (Invitrogen) and 2 mM
Glutamine (Invitrogen). BJAB (a kind gift from Michaela Gack,
NEPRC, Harvard Medical School), 309-98 and 211-98 rhesus B
cell lines (both a kind gift from Fred Wang, Harvard Medical
School) were kept in RPMI supplemented with 20% FBS, 25 mM
HEPES, 100 Units/ml Penicillin, 100 mg/ml Streptomycin, 1 mM
sodium pyruvate (Invitrogen) and 2 mM Glutamine. All endothe-
lial cells were cultured in EGM-2 endothelial growth medium
(Lonza) and culture vessels were pre-coated with Attachment
Factor (Invitrogen). Human umbilical vein endothelial cells
(HUVEC) cells were purchased from Lonza. Lymphatic endothe-
lial cells (LEC) from juvenile donors were purchased from
Promocell. R8 telomerase immortalized rhesus endothelial cells
and primary rhesus microvascular endothelial cells were a kind gift
from Jay Nelson (Oregon Health & Science University).
Large scale transfection of 293T cells for protein production was
performed using the Mammalian Cell Profection Calcium
Phosphate Kit (Promega) with 20 mg DNA per 10 cm cell culture
dish. Small scale transfection for FACS analysis was performed
using LipofectamineLTX and Plus reagent (Invitrogen) according
to the manufacturer’s protocol with a DNA(mg):Plus(ml):Lipofecta-
mineLTX(ml) ratio of 1:1:1.
Plasmids
All Eph coding sequences were cloned into the pcDNA4amy-
chis (Invitrogen) backbone vector via appropriate restriction
enzymes. cDNAs were obtained by RT-PCR from 293T cells
and from commercial sources where necessary and sequences are
representative of the NCBI reference sequence if not stated
otherwise (Suppl. Table S1). Sequence similarity with orthologs
was determined using the BLAST algorithm [45]. The EphB6
construct has a conservative amino acid exchange E998D. Viral
gH and gL cDNAs were cloned into the pcDNA6aV5His
(Invitrogen) backbone. Sequence identity was verified by DNA
sequencing from both ends. The sequence of RRV 26-95 gH and
gL was codon-optimized for expression as described elsewhere
[46]. The soluble ectodomains of gH from RRV 26-95 (amino
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peptide were inserted behind a heterologous signal peptide of
murine IgG-kappa into pAB61Strep in a fashion analogous to
KSHV gH/gL [47], resulting in C-terminally fused IgG1 Fc-
fusion proteins (gH-Fc) with a tandem Strep-Tag at the C-
terminus.
Recombinant proteins
Proteins bearing a tandem Strep-Tag at their C-terminus were
purified from 293T cell culture supernatant. 293T cells were
transfected by calcium phosphate transfection with expression
plasmids based on the pAB61Strep vector described earlier [47].
The protein-containing cell culture supernatant was first filtered
through 0.22 mm PES membranes (Millipore) and then passed over
0.5 ml of a Streptactin (Qiagen) matrix in a gravity flow Omniprep
column (BioRad). Bound protein was washed with 50 ml phosphate
buffered saline pH 7.4 (PBS) (Invitrogen) and eluted in 1 ml
fractions with 3 mM desthiobiotin (Sigma-Aldrich) in PBS. Protein
concentration was determined by absorbance at 280 nm. Aliquots
were frozen and stored at 280 degrees Celsius. Soluble Eph-Fc and
Ephrin-Fc fusion proteins were purchased from R&D Systems.
Virus and entry assays
RRV-GFP 26-95 [48] was grown on primary rhesus fibroblasts.
A confluent T175 flask (Corning) was inoculated with app.
50 000 PFU RRV-GFP 26-95, resulting in a multiplicity of
infection below 0.001. Virus was allowed to replicate until the
cell lawn was completely destroyed (approximately three weeks).
The cell culture supernatant was cleared by centrifugation for
10 min at 3000 g and further stored at 4 degrees Celsius. A
filtration step was left out as we observed a relatively strong
retention of virus in some 0.45 mM filters and found the
supernatant to be free of visible debris or GFP containing particles
after centrifugation. The virus stock was diluted 1:5 in cell culture
medium for infection, and was tested on 293T cells consistently
yielding around 20% green cells two days post infection. We did
not observe a noticeable drop in virus titer over approximately 6
months. RRV-YFP 26-95 (to be described in detail in another
manuscript) encodes an YFP expression cassette at the same locus
as the GFP cassette in RRV-GFP and is derived from the RRV
26-95 BAC [49]. For high titer infection, virus was concentrated in
a JA20 fixed angle rotor for 2 h at 50 000 g.
KSHV.219 was prepared from iSLK.219 cells [50]. The cells
were induced with 1 mg/ml doxycyclin (Sigma-Aldrich) and kept
in this medium for one week. Supernatant was then collected,
cleared by centrifugation for 10 min at 3000 g, filtered through a
0.45 mm PES vacuum filter (Millipore) and stored at 4 degrees
Celsius. The virus stock was diluted 1:5 in cell culture medium and
was tested on 293T cells and consistently yielded around 20–50%
infected cells after two days. We did not observe a noticeable drop
in virus titer over approximately 4 months.
For blocking experiments, a functional MOI in the range of 0.1
was targeted where possible as this allows for enough dynamic
range without over-saturating the entry assay. Infection in that
range was achieved by using our virus stock at 1:5 dilution. Entry
was quantified by flow cytometry on day two post infection unless
otherwise stated, with sample sizes of 10 000 cells or more. Where
indicated, a commercial LIVE/DEAD fixable far red (Invitrogen)
exclusion dye viability assay was included.
Infection of BJAB cells with rKSHV.219 was achieved by
inducing iSLK.219 cells with 2.5 mg/ml doxycyclin in 200 ml
DMEM with 10% FBS in a 48 well plate. The general protocol
was taken from Myoung et al. [7] with slight modification. BJAB
cells were added after one day in 200 ml RPMI with 10% FBS.
After the desired length of co-culture, the cells were harvested by
vigorous pipetting in PBS, fixed with 2% paraformaldehyde (Santa
Cruz) and stained with anti-CD20 clone L27 (10 mg/ml)
(BectonDickenson) followed by anti-mouse-Cy5 (Southern Biotec),
all in 10% goat serum in PBS (Invitrogen). The cells were then
analyzed by flow cytometry. In a first gating step, the B cells were
separated by FSC/SSC analysis from the iSLK.219 cells. This step
was followed by another gate for Cy5-high CD20-positive cells.
This CD20-positive population was then analyzed for expression
of the GFP reporter gene. As additional controls, BJAB were
incubated with non-induced iSLK.219 cells, and induced
iSLK.219 cells cultured without BJAB cells were analyzed.
Lentiviruses pseudotyped with VSV-G and A-MLV glycopro-
tein were produced as described elsewhere [51]. Briefly,
SIVmac239 encoding a GFP expression cassette instead of the
nef gene and deleted in the env locus was transfected into 293T
cells together with the respective glycoprotein expression-plasmid
to produce infectious virus. The A-MLV expression plasmid was a
kind gift from Michael Farzan, Harvard Medical School.
All experiments were performed as biological replicates with the
number of replicates as indicated (n=2, 3, or 4). Error bars always
indicate standard deviation (sd) or range for n=2.
Affinity-purification of gH/gL-interacting proteins
Soluble gH-FcStrep/gL constructs from RRV 26-95 and 17577
and KSHV as well as FcStrep as a control were expressed in 293T
cells. 15 ml of protein-containing supernatant were coupled to
Streptactin beads (Qiagen) for 4 h. The beads were then washed
and incubated with the lysate of 293T cells (app. 10
9 cells per
sample in 10 ml). Lysates were prepared in 1% NP40 150 mM
NaCl 20 mM HEPES 1 mM EDTA with protease inhibitor
cocktail (Roche) and cleared by centrifugation for 1 h at 20000 g
in 1.5 ml tubes. After overnight incubation with the lysate, the
Streptactin beads were washed twice briefly with 1% NP40 in PBS
and then eluted with 3 mM Desthiobiotin (Sigma-Aldrich) in
0.375% NP40 in PBS. Eluates were re-precipitated with ProteinG
sepharose beads (GE Healthcare) for 1 h. The ProteinG beads
were then washed briefly 36 with 1% NP40 in PBS, heated in
SDS-sample buffer and subjected to electrophoresis on 8–16%
gradient Laemmli gels (Invitrogen). Gels were stained with either
colloidal coomassie SafeStain (Invitrogen) or SilverQest silver
staining kit (Invitrogen). Visible bands were excised and sent to
Taplin Mass Spectrometry Core Facility at Harvard Medical
School for tryptic digest, LC-MS/MS analysis and database
search.
Flow cytometry based binding assay
293T cells were transfected with the respective Eph constructs.
Two days after transfection, the cells were harvested without
trypsinization in cold PBS and fixed for 10 min in 2%
paraformaldehyde in PBS on ice, followed by 5 min of
permeabilization in 0.1% NP40 in PBS. The cells were then
blocked for 2 h in binding buffer (10% FBS in PBS) and incubated
with the indicated Fc-fusion proteins at a concentration of
approximately 10 nM (3 mg/ml as determined by A280 for gH-
Fc/gL fusions) in binding buffer for 1 h. The cells were then
washed in 306the original volume in binding buffer for 1 h and
then incubated with goat anti-human-Alexa488 (Invitrogen) 1:100
and goat anti-mouse-Cy5 (Southern Biotech) secondary antibody
1:100 for 1 h, followed by two washes for 30 min in 306 the
original volume in PBS. The cells were then post-fixated and
stored in 100 ml 2% paraformaldehyde in PBS until analysis on a
FACScalibur (BectonDickinson). Flow cytometry files were ana-
lyzed using FloJo Version 8.8.7 (Tree Star).
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HUVEC cells and rhesus fibroblasts were infected with RRV-YFP
26-95 (approximately 10
8 viral genome copies in 800 mli nas i x w e l l
plate and conditions that usually yield 70–95% infected rhesus
fibroblasts or HUVEC, respectively) for 4 h. Virus was removed, the
cells were washed 26 with PBS and harvested in 900 ml0 . 0 5 %
Trypsin/EDTA solution (Invitrogen). Trypsin was stopped by
addition of 100 ml FBS and the cells were pelleted for 5 min at
500 g in a microcentrifuge tube. The cell pellet was resuspended by
vortexing in PBS and pelleted again. Nuclei were isolated in Nuclei
EZ Prep buffer (Sigma-Aldrich) according to the manufacturer’s
recommendations. All isolation steps were carried out on ice and with
apre-chilledcentrifuge.Briefly,150 ml Nuclei EZPrep buffer (Sigma-
Aldrich) were added and the pellet was resuspended by 2 s of
vortexing, followed by addition of 1 ml of Nuclei EZ Prep buffer and
1 s of vortexing. The cells were then incubated on ice for 10 min.
Nuclei were pelleted at 500 g for 5 min and the supernatant was
discarded. Resuspension, vortexing, and incubation in Nuclei EZ
Prep buffer was repeated as above and the nuclei were pelleted again,
discarding the supernatant. As an additional purification step, the
nuclei pellet was resuspended in 1 ml of 6% iodixanol in PBS by brief
vortexing. The nuclei were re-pelleted at 20000 g for 30 s. The
supernatant was discarded and the nuclei were stored at 220C for
analysis. Total nucleic acid was extracted using the Qiaamp (Qiagen)
kit. Genomic viral DNA (LANA locus; forward primer: AC-
CGCCTGTTGCGTGTTA, reverse primer: CAATCGC-
CAACGCCTCAA, probe: CAGGCCCCATCCCC) and the cellu-
lar GAPDH locus (assay ID Hs02786624_g1, Applied Biosystems;
primers and probe recognize both human and rhesus) were
quantified by Taqman Realtime PCR using a LANA containing
cosmid as RRV standard and serially diluted genomic cellular DNA
as GAPDH standard. Three independent experiments were
performed. Realtime PCR quantification was performed in dupli-
cates. Results were normalized to the average LANA/genomic DNA
ratio in each cell type with control protein (EGFR-Fc) set to 100%.
Supporting Information
Figure S1 Gating strategy for flow cytometry binding
assay. 293T cells were transfected with expression plasmids for
myc epitope-tagged Eph proteins. The cells were fixed and
permeabilized and incubated with anti-myc monoclonal antibody
and either gH-Fc/gL or Fc control protein. Myc-antibody or bound
Fc-fusion protein was detected with anti-mouse-Cy5 and anti-
human-Alexa488 secondary antibodies. Exemplarily, cells trans-
fected with empty vector, EphA2 or EphB4 expression plasmids are
shown after incubation with either Fc or KSHV gH-Fc/gL. In each
zebra plot, the coloration represents the density of events. The
geometric mean of the intensities for Alexa488 and Cy5 in the area
of analysis was determined and the ratio calculated.
(TIF)
Figure S2 Binding preferences of A-type Ephrins for
EphA2, EphA4 and EphA5. 293T cells were transfected with
the indicated Eph-constructs (myc-tag). The cells were lysed and
equal amounts of lysate were immunoprecipitated with 1 mg of the
recombinant Ephrin-Fc proteins. After washing three times with
lysis buffer, bound protein was detected by Western Blot analysis.
(TIF)
Figure S3 Effects of MOI or time of measurement on
apparent RRV entry into cells. (A) Rhesus fibroblasts and
HUVEC were infected with RRV-YFP 26-95 at different MOIs. The
viral inoculum was pre-incubated with EphB3-Fc (black boxes, solid
line) or EGFR-Fc (black diamonds, dashed line) at 10 mg/ml for
45 min. Entry was quantified by flow cytometry two days after
infection as number of YFP-positive cells. (n=2, error bar represents
range; if not visible, range is smaller than chart symbol) (B)T h e
geometric mean fluorescence intensity of the YFP reporter gene was
quantified from the same samples as in (B). (C) Percent inhibition
achieved at different MOIs based on the percentage of green rhesus
fibroblasts (black triangles, solid line) or HUVEC (black circles, dotted
line). (D) Fold reduction in YFP fluorescence based on GFP
fluorescence measured in rhesus fibroblasts (black triangles, solid line)
or HUVEC (black circles, dotted line). (E) Rhesus fibroblasts and
HUVEC were infected with RRV-GFP 26-95 which was pre-
incubated with increasing concentrations of EphB3-Fc (black boxes,
solid line) or Fc (control, black diamonds, dashed line). Entry was
quantified as the number of GFP positive cells by flow cytometry 24 h
post infection. (n=2, error bar represents range)
(TIF)
Table S1 Table of NCBI database accession numbers
for Eph DNA sequences, protein sequences, and per-
centages of amino acid identity with rhesus monkey and
mouse orthologs.
(PDF)
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